Advanced Lung Cancer Clinical Trial
Official title:
A Clinical Study of 35 kDa Hyaluronan Fragment in Treatment of Pain and Discomfort Associated With Advanced Lung Cancer
In this research, the patients with advanced lung cancer accompanied by pain and discomfort were treated by injecting freshly manufactured tissue permeable hyaluronan fragment HA35 into the tissue under abdominal adipose.
Pain is generally considered the most common symptom of lung cancer. The three most common causes of pain in patients with advanced lung cancer are: 1. metastasis of lung cancer to the bones, which accounts for approximately 34 percent of lung cancer pain; 2. Presence of a Pancoast tumor, located at the top of the lung close to the brachial plexus nerves and cervical sympathetic nerves, which accounts for approximately 31 percent of lung cancer pain; 3. Spread of the cancer into the chest wall, accounting for approximately 21 percent of lung cancer pain. Palliative care is a specialized field that aims to alleviate symptoms and maximize the patient's quality of life. Palliative care does not focus on curing the disease or prolonging life, which is the goal of other cancer treatments, such as chemotherapy. However, palliative care is an important part of the patient's treatment plan and encompasses physical symptoms, psychosocial distress, spiritual distress, and caregiver distress. The management of pain due to lung cancer may include a combination of medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioids (pain medications), and antidepressants. For metastases to the bone, radiation therapy and the use of bisphosphonates (drugs to help prevent bone breakdown) can alleviate pain. In addition, smoking cessation (stopping smoking) is recommended, as surveys have revealed that lung cancer patients who continue to smoke after diagnosis have a higher incidence of pain and other lung cancer complications than nonsmokers and those who quit smoking. While pain is the most common symptom of lung cancer, other symptoms include: persistent coughing,wheezing,shortness of breath,hoarseness,weight loss,loss of appetite,fatigue or feeling weak and respiratory infections (like bronchitis or pneumonia) that don't go away or keep returning. Hyaluronidase PH20 produced 35 kDa tissue permeable low molecular weight hyaluronan fragment by cutting high molecular hyaluronan. The previous clinical studies had shown that local injection of 35 kDa hyaluronan fragment effectively relieved inflammatory pain and neuropathic pain and promoted chronic wound healing. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04575831 -
Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)
|
N/A | |
Completed |
NCT04069494 -
Descriptors and Predictors of Burden and Information Needs
|
||
Terminated |
NCT03330834 -
CAR-T Cell Immunotherapy for Advanced Lung Cancer
|
Phase 1 | |
Withdrawn |
NCT03004105 -
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Withdrawn |
NCT03501056 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05279521 -
The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.
|
N/A | |
Terminated |
NCT02768337 -
Cambridge Brain Mets Trial 1
|
Phase 1/Phase 2 | |
Completed |
NCT04672369 -
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
|
Phase 1 | |
Recruiting |
NCT03751592 -
Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05431569 -
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06456138 -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
Completed |
NCT04672356 -
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT06107894 -
TIL Therapy for Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06183762 -
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
|
||
Recruiting |
NCT05664971 -
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05815862 -
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
Recruiting |
NCT06106152 -
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
|
Early Phase 1 |